Trump's 100% tariffs on branded drugs: Indian generics spared but poses risks for pharma sector – Explained
US President Trump announced a 100% tariff on imported branded and patented pharmaceuticals starting October 2025, aiming to boost domestic manufacturing. Indian generic drug makers are largely unaffected initially, but concerns loom over potential tariff expansion to complex generics. Sun Pharma faces significant exposure due to its US branded portfolio.
US President Trump announced a 100% tariff on imported branded and patented pharmaceuticals starting October 2025, aiming to boost domestic manufacturing. Indian generic drug makers are largely unaffected initially, but concerns loom over potential tariff expansion to complex generics. Sun Pharma faces significant exposure due to its US branded portfolio. What's Your Reaction?
